Olezarsen · Tryngolza

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hypertriglyceridemia · Phase 3 · investigational in the US

Also approved (2)
CA
  • Adjunct to diet in adult patients for the treatment of FCS (Notice of Compliance date from the CDA-AMC review; sponsor Theratechnologies Inc.)
Product first approved 2025canjhealthtechnol.ca
EU
  • Adjunct to diet in adults with genetically confirmed familial chylomicronemia syndrome; marketing authorisation holder Swedish Orphan Biovitrum AB (Sobi)
Product first approved 2025EMA

Company guidance: regulatory decision expected fourth quarter of 2026 (Ionis Pharmaceuticals, 9 Nov 2026). “FCS launch outside the U.S. underway; received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for sHTG (sHTG fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]), paving the way to bring TRYNGOLZA to sHTG patients across Europe with a final approval decision expected in the fourth quarter of 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Familial Chylomicronemia Syndrome
NCT07727538 · Ionis Pharmaceuticals, Inc.
2026-07-31 – 2031-08 · Familial Chylomicronemia Syndrome
What this study did
NCT05130450 · Ionis Pharmaceuticals, Inc.
2021-11-18 – 2028-02 · Familial Chylomicronemia Syndrome
What this study did
NCT05185843 · Ionis Pharmaceuticals, Inc.
2022-02-25 – 2027-06 · Familial Chylomicronemia Syndrome
What this study did
Severe Hypertriglyceridemia
NCT05681351 · Ionis Pharmaceuticals, Inc.
2022-12-13 – 2027-03 · Severe Hypertriglyceridemia
What this study did
Phase 2 (2)
Hypertriglyceridemia
NCT03385239 · Akcea Therapeutics
2018-01-30 – 2020-02-25 · Hypertriglyceridemia, Cardiovascular Diseases
What this study did
Severe Hypertriglyceridemia
NCT05355402 · Ionis Pharmaceuticals, Inc.
2022-05-09 – 2023-12-21 · Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
What this study did
Phase 1 (2)
Other / comorbidity
NCT05579860 · Ionis Pharmaceuticals, Inc.
2022-10-05 – 2023-05-22 · Healthy Participants
What this study did
NCT02900027 · Ionis Pharmaceuticals, Inc.
2016-09 – 2018-04-30 · Elevated Triglycerides (TG)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hypertriglyceridemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olezarsen (Tryngolza): this drugPhase 3RNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaReliable signal
NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083.
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signal
NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22).
Pravafenix
Phase 3(overall)
Small moleculeHMG-CoA reductase / PPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
Saroglitazar (Lipaglyn)
Phase 3(overall)
Small moleculePPAR-alpha/PPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
BW-00112Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
MAR001Phase 2Monoclonal antibodyANGPTL4Weak signalFeatured results are safety only in this race
RBD5044Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SYH2070
Phase 2(overall)
RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
TipelukastPhase 2Small moleculeCysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenaseWeak signal
NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results.
TLC-2716Phase 2Small moleculeLiver X receptor (LXR)not yet gradedNo reviewed efficacy summary in this indication
JMT202Phase 1/2Monoclonal antibodyβ-Klotho (KLB)not yet gradedNo reviewed efficacy summary in this indication
RN0361Phase 1/2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ALN-APOC3
Phase 1(overall)
RNA / oligonucleotideApolipoprotein C-III (APOC3)not yet gradedNo reviewed efficacy summary in this indication
ISH0688Phase 1Protein / enzyme therapeuticFGF21 receptornot yet gradedNo reviewed efficacy summary in this indication
Kylo-12Phase 1RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
VERVE-201Phase 1Gene therapy / editingANGPTL3 gene (hepatocyte genomic DNA)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tryngolza (Olezarsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 3Severe HypertriglyceridemiaActive not recruiting
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 3Familial Chylomicronemia SyndromeRecruiting
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
19 May 2025Topline resultPhase 3 Essence (NCT05610280) of olezarsen met its primary endpoint
Ionis Pharmaceuticals · Source ↗